# Registry For Temsirolimus, Sunitinib, And Axitinib Treated Patients With Metastatic Renal Cell Carcinoma (mRCC), Mantle Cell Lymphoma (MCL), And Gastro-Intestinal Stroma Tumor (GIST) [STAR-TOR]

> **NCT00700258** · — · COMPLETED · sponsor: **Pfizer** · enrollment: 1520 (actual)

## Conditions studied

- Carcinoma, Renal Cell, Advanced
- Lymphoma, Mantle-Cell
- Gastrointestinal Stroma Tumors

## Interventions

- **DRUG:** Temsirolimus
- **DRUG:** Temsirolimus
- **DRUG:** Sunitinib
- **DRUG:** Sunitinib
- **DRUG:** Axitinib

## Key facts

- **NCT ID:** NCT00700258
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2008-02-13
- **Primary completion:** 2021-12-28
- **Final completion:** 2021-12-28
- **Target enrollment:** 1520 (ACTUAL)
- **Last updated:** 2024-09-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00700258

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00700258, "Registry For Temsirolimus, Sunitinib, And Axitinib Treated Patients With Metastatic Renal Cell Carcinoma (mRCC), Mantle Cell Lymphoma (MCL), And Gastro-Intestinal Stroma Tumor (GIST) [STAR-TOR]". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT00700258. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*